COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K6XI
|
|||
| Drug Name |
Griffithsin
|
|||
| Synonyms |
GRFT
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Severe acute respiratory syndrome (SARS) | Preclinical | [1] | |
| Other Indication | Human immunodeficiency virus infection | Phase 1 | [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | SARS-CoV spike glycoprotein (S) | Target Info | Blocker | [1] |
| Griffithsin, an antiviral protein, binds specifically to oligosaccharides on viral surface glycoproteins such as S of SARS-CoV to inhibit CoV entry. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 2 | ClinicalTrials.gov (NCT02875119) Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.